Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 4 (2007), Issue 6 (June)

1. Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate.
   Oncogene, 26(26): 3904-8. [Abstract] [Full-text]
2. Opportunities for improving the therapeutic ratio for patients with sarcoma.
   Lancet Oncol, 8(6): 513-24. [Abstract] [Full-text]
3. Chordoma.
   Curr Opin Oncol, 19(4): 367-70. [Abstract] [Full-text]
4. Second line therapies for the treatment of gastrointestinal stromal tumor.
   Curr Opin Oncol, 19(4): 353-8. [Abstract] [Full-text]
5. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
   Cancer Res, 67(11): 5489-97. [Abstract] [Full-text]
6. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
   Cancer Res, 67(11): 5300-7. [Abstract] [Full-text]
7. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants.
   Clin Cancer Res, 13(11): 3363-9. [Abstract] [Full-text]
8. The treatment of polycythaemia vera: an update in the JAK2 era.
   Intern Emerg Med, 2(1): 13-8. [Abstract] [Full-text]
9. Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells.
   Blood, 109(12): 5411-21. [Abstract] [Full-text]
10. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors.
    Oncogene, 26(27): 3909-19. [Abstract] [Full-text]
11. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.
    Blood, 109(12): 5143-50. [Abstract] [Full-text]
12. BCR-ABL mutant kinetics in CML patients treated with dasatinib.
    Leuk Res, 31(6): 865-8. [Abstract] [Full-text]
13. Recent advances in the understanding of mastocytosis: the role of KIT mutations.
    Br J Haematol, 138(1): 12-30. [Abstract] [Full-text]
14. Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia.
    Br J Haematol, 138(1): 77-81. [Abstract] [Full-text]
15. N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity.
    Leuk Res, 31(8): 1085-95. [Abstract] [Full-text]
16. Local management of adult soft tissue sarcomas.
    Semin Oncol, 34(3): 256-69. [Abstract] [Full-text]
17. A modification of NIH consensus criteria to better distinguish the highly lethal subset of primary localized gastrointestinal stromal tumors: a subdivision of the original high-risk group on the basis of outcome.
    Surgery, 141(6): 748-56. [Abstract] [Full-text]
18. Characterization of Ph-negative abnormal clones emerging during imatinib therapy.
    Cancer, 109(12): 2466-72. [Abstract] [Full-text]
19. Pivanex, a histone deacetylase inhibitor, induces changes in BCR-ABL expression and when combined with STI571, acts synergistically in a chronic myelocytic leukemia cell line.
    Leuk Res, 31(8): 1115-23. [Abstract] [Full-text]
20. A review of resistance patterns and phenotypic changes in gastrointestinal stromal tumors following imatinib mesylate therapy.
    J Gastrointest Surg, 11(6): 758-66. [Abstract] [Full-text]
21. Reducing uncertainty in health-care resource allocation.
    Br J Cancer, 96(12): 1834-8. [Abstract] [Full-text]
22. Inhibition of gut pacemaker cell formation from mouse ES cells by the c-kit inhibitor.
    Biochem Biophys Res Commun, 359(2): 354-9. [Abstract] [Full-text]
23. Sunitinib malate.
    Cancer Chemother Pharmacol, 60(3): 357-64. [Abstract] [Full-text]
24. Identification and functional signature of genes regulated by structurally different ABL kinase inhibitors.
    Oncogene, 26(28): 4179-88. [Abstract] [Full-text]
25. Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy.
    Int J Clin Oncol, 12(3): 212-7. [Abstract] [Full-text]
26. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype.
    Clin Pharmacol Ther, 82(1): 33-40. [Abstract] [Full-text]
27. Molecular cytogenetic findings in a four-way t(1;12;5;12)(p36;p13;q33;q24) underlying the ETV6-PDGFRB fusion gene in chronic myelomonocytic leukemia.
    Cancer Genet Cytogenet, 176(1): 67-71. [Abstract] [Full-text]
28. Gastrointestinal stromal tumors involving the prostate: presentation, course, and therapeutic approach.
    Urology, 69(6): 1209.e5-7. [Abstract] [Full-text]
29. Control of aggressive fibromatosis by treatment with imatinib mesylate. A case report and review of the literature.
    J Cancer Res Clin Oncol, 133(8): 533-8. [Abstract] [Full-text]
30. Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses.
    Arch Dermatol, 143(6): 736-40. [Abstract] [Full-text]
31. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance.
    Blood, 110(1): 313-22. [Abstract] [Full-text]
32. The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1.
    Leukemia, 21(7): 1395-404. [Abstract] [Full-text]
33. Imatinib mesylate inhibits in vitro and ex vivo biologic responses related to vascular occlusion in giant-cell arteritis.
    Ann Rheum Dis. [Abstract] [Full-text]
34. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor.
    Ann Surg Oncol, 14(7): 2018-27. [Abstract] [Full-text]
35. Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406.
    Cancer Sci, 98(8): 1223-5. [Abstract] [Full-text]
36. Imatinib in the treatment of follicular dendritic sarcoma: a case report and review of literature.
    Onkologie, 30(7): 381-4. [Abstract] [Full-text]
37. Eosinophilic leukaemia.
    Br Med Bull, 81: 115-27. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.